Biogen receives Tell Award for demonstrating successful scientific and technological innovation in Switzerland
Biogen (NASDAQ: BIIB), one of the oldest independent biotechnology companies, has won the 2016 Tell Award. The Award, presented in New York by Switzerland Global Enterprise based on nominations from the Cantonal authorities, honors U.S. companies for innovation in Switzerland.
Zug, Switzerland – 16th June, 2016
The Tell Award recognizes those companies that “boldly accept the risks and rewards that come with international expansion and demonstrate success with operations in Switzerland”. Ambassador André Schaller, Consul General of Switzerland in New York, and Daniel Küng, CEO of Switzerland Global Enterprise, handed over this year’s Tell Award to three companies, including Biogen. John Cox, Executive Vice President Pharmaceutical Operations & Technology, and Johanna Friedl-Naderer, Senior Vice President, Head Europe & Canada, received the award on behalf of Biogen at a ceremony in New York City, followed by a panel discussion about the dynamics of successful companies from inventions to strategic investments.
“It is a great honor to receive this award. Biogen has a long-standing heritage and focus on science, and a deep commitment to improving the lives of people with serious medical conditions. Switzerland is an ideal location for Biogen to continuously develop and provide access to innovative therapies to people living with serious diseases, today and tomorrow,” said Johanna Friedl-Naderer.
Important investments in Switzerland
Biogen is currently building a next-generation manufacturing facility in Solothurn, with the goal of helping the company to meet the rising global demand for high-quality biopharmaceuticals. The facility will create up to 400 new jobs for highly-skilled employees, and represents both Switzerland`s and Biogen`s pursuit of scientific and technological innovation.
“I am glad to strengthen our connections with Switzerland. The next-generation manufacturing facility will be another essential component of Biogen’s long term strategic objectives and guarantee access to life-changing therapies in the years to come to millions of patients around the world. The Tell Award recognizes our important partnership, and I am delighted to be here receiving it today,” said John Cox.
For additional information please visit
www.biogen-international.com and www.biogen-solothurn.ch
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.
Markus A. Ziegler,
Director Corporate Affairs Switzerland
Phone: +41 41 728 74 36.